Does the media favor JAZZ or INDV?

In the previous week, Jazz Pharmaceuticals had 14 more articles in the media than Indivior. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Jazz Pharmaceuticals' score of 0.15 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NBIX or INDV?

In the previous week, Neurocrine Biosciences had 2 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Neurocrine Biosciences and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Neurocrine Biosciences' score of 0.60 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INDV or CORT?

In the previous week, Corcept Therapeutics had 16 more articles in the media than Indivior. MarketBeat recorded 20 mentions for Corcept Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Corcept Therapeutics' score of 0.17 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ELAN or INDV?

In the previous week, Elanco Animal Health had 6 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Elanco Animal Health's score of 0.29 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INDV or RDY?

In the previous week, Indivior had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Indivior and 1 mentions for Dr. Reddy's Laboratories. Indivior's average media sentiment score of 1.40 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Indivior (INDV) Competitors

$35.83 +0.38 (+1.07%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$35.15 -0.68 (-1.90%)

As of 10/9/2026 07:30 PM Eastern

Compare

INDV vs. JAZZ, NBIX, CORT, ELAN, and RDY

Should you buy Indivior stock or one of its competitors? Indivior's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Dr. Reddy's Laboratories (RDY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Indivior compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Jazz Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Indivior has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Indivior has lower revenue, but higher earnings than Jazz Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.08	-$356.15M	$14.50	15.06
Indivior	$1.33B	3.18	$210M	$2.79	12.84

In the previous week, Jazz Pharmaceuticals had 14 more articles in the media than Indivior. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Jazz Pharmaceuticals' score of 0.15 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals currently has a consensus price target of $291.25, suggesting a potential upside of 33.34%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 26.06%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a net margin of 26.65% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Indivior	26.65%	-283.11%	36.85%

Summary

Jazz Pharmaceuticals beats Indivior on 9 of the 15 factors compared between the two stocks.

How does Indivior compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Neurocrine Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Indivior has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 2 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Neurocrine Biosciences and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Neurocrine Biosciences' score of 0.60 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a net margin of 26.65% compared to Neurocrine Biosciences' net margin of 20.91%. Neurocrine Biosciences' return on equity of 22.43% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Indivior	26.65%	-283.11%	36.85%

Neurocrine Biosciences has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.29	$478.60M	$6.82	20.89
Indivior	$1.33B	3.18	$210M	$2.79	12.84

Neurocrine Biosciences currently has a consensus target price of $202.05, suggesting a potential upside of 41.85%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 26.06%. Given Neurocrine Biosciences' higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Neurocrine Biosciences beats Indivior on 11 of the 16 factors compared between the two stocks.

How does Indivior compare to Corcept Therapeutics?

Indivior (NASDAQ:INDV) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Indivior has a net margin of 26.65% compared to Corcept Therapeutics' net margin of 6.52%. Corcept Therapeutics' return on equity of 8.26% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Corcept Therapeutics	6.52%	8.26%	6.45%

Indivior has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Indivior has higher revenue and earnings than Corcept Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.33B	3.18	$210M	$2.79	12.84
Corcept Therapeutics	$761.41M	17.21	$99.65M	$0.42	288.55

Indivior presently has a consensus price target of $45.17, suggesting a potential upside of 26.06%. Corcept Therapeutics has a consensus price target of $138.17, suggesting a potential upside of 14.01%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Corcept Therapeutics had 16 more articles in the media than Indivior. MarketBeat recorded 20 mentions for Corcept Therapeutics and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Corcept Therapeutics' score of 0.17 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.3% of Indivior shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Indivior beats Corcept Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Indivior has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.43	-$232M	-$0.41	N/A
Indivior	$1.33B	3.18	$210M	$2.79	12.84

In the previous week, Elanco Animal Health had 6 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Elanco Animal Health's score of 0.29 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a net margin of 26.65% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Indivior	26.65%	-283.11%	36.85%

Elanco Animal Health presently has a consensus price target of $29.70, suggesting a potential upside of 29.59%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 26.06%. Given Elanco Animal Health's higher probable upside, equities research analysts plainly believe Elanco Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Elanco Animal Health has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Indivior has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Summary

Elanco Animal Health and Indivior tied by winning 8 of the 16 factors compared between the two stocks.

How does Indivior compare to Dr. Reddy's Laboratories?

Indivior (NASDAQ:INDV) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 26.06%. Dr. Reddy's Laboratories has a consensus target price of $1,450.00, suggesting a potential upside of 11,523.25%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Indivior had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Indivior and 1 mentions for Dr. Reddy's Laboratories. Indivior's average media sentiment score of 1.40 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has a net margin of 26.65% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

60.3% of Indivior shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.33B	3.18	$210M	$2.79	12.84
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35

Indivior has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Summary

Indivior beats Dr. Reddy's Laboratories on 11 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.18B	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	12.84	797.58	274.15	26.16
Price / Sales	3.18	756.50	590.34	94.78
Price / Cash	13.03	85.97	76.38	53.09
Price / Book	-45.94	10.71	11.21	6.34
Net Income	$210M	$2.84B	$3.50B	$381.90M
7 Day Performance	0.34%	-0.93%	-0.90%	-1.41%
1 Month Performance	3.82%	-4.91%	-4.44%	-3.48%
1 Year Performance	50.67%	-4.13%	6.96%	1.16%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	4.5161 of 5 stars	$35.83 +1.1%	$45.17 +26.1%	+48.4%	$4.18B	$1.33B	12.84	838	Positive News High Trading Volume
JAZZ Jazz Pharmaceuticals	4.2367 of 5 stars	$231.96 -1.7%	$291.15 +25.5%	+58.1%	$15.09B	$4.27B	16.03	2,890	Trending News Analyst Forecast Insider Trade
NBIX Neurocrine Biosciences	4.778 of 5 stars	$142.95 -0.9%	$202.05 +41.3%	+2.9%	$14.52B	$2.86B	20.94	2,000	Analyst Forecast
CORT Corcept Therapeutics	3.9639 of 5 stars	$116.59 -4.5%	$138.17 +18.5%	+37.2%	$12.58B	$761.41M	277.11	730
ELAN Elanco Animal Health	3.8259 of 5 stars	$22.66 +0.7%	$29.70 +31.1%	+14.2%	$11.31B	$5.02B	N/A	9,400	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and RDY

How does Indivior compare to Jazz Pharmaceuticals?

Summary

How does Indivior compare to Neurocrine Biosciences?

Summary

How does Indivior compare to Corcept Therapeutics?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

How does Indivior compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and RDY

How does Indivior compare to Jazz Pharmaceuticals?

Which has more risk and volatility, JAZZ or INDV?

Do institutionals and insiders hold more shares of JAZZ or INDV?

Which has higher earnings & valuation, JAZZ or INDV?

Does the media favor JAZZ or INDV?

Do analysts recommend JAZZ or INDV?

Is JAZZ or INDV more profitable?

Summary

How does Indivior compare to Neurocrine Biosciences?

Which has more risk and volatility, NBIX or INDV?

Does the media prefer NBIX or INDV?

Is NBIX or INDV more profitable?

Which has higher earnings and valuation, NBIX or INDV?

Do analysts rate NBIX or INDV?

Do institutionals & insiders hold more shares of NBIX or INDV?

Summary

How does Indivior compare to Corcept Therapeutics?

Is INDV or CORT more profitable?

Which has more risk and volatility, INDV or CORT?

Which has higher valuation & earnings, INDV or CORT?

Do analysts prefer INDV or CORT?

Does the media prefer INDV or CORT?

Do institutionals and insiders hold more shares of INDV or CORT?

Summary

How does Indivior compare to Elanco Animal Health?

Do institutionals & insiders hold more shares of ELAN or INDV?

Which has better earnings and valuation, ELAN or INDV?

Does the media favor ELAN or INDV?

Is ELAN or INDV more profitable?

Do analysts rate ELAN or INDV?

Which has more risk and volatility, ELAN or INDV?

Summary

How does Indivior compare to Dr. Reddy's Laboratories?

Do analysts recommend INDV or RDY?

Does the media refer more to INDV or RDY?

Is INDV or RDY more profitable?

Do insiders & institutionals hold more shares of INDV or RDY?

Which has better valuation & earnings, INDV or RDY?

Which has more risk and volatility, INDV or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools